exciting progress in elucidating the mechanisms of bortezomib in lymphoma

[Guest guest]

This item describes how correlative studies are beginning to pay off . by

identifying biomarkers that predict response to therapy - in this case to

Velcade.

==

Study makes exciting progress in elucidating the mechanisms of bortezomib in

lymphoma http://bit.ly/bp41uC

Copying a snip:

" In the current study's examination of biomarkers of interest, the

researchers found that elevated Ki-67, a protein associated with cell

proliferation, was a marker of poor prognosis.

....Elevated NF-KB measured by p65, a subunit of a protein complex that plays

a key role in inflammation, immune response and cell survival, demonstrated

a trend toward longer time to disease progression, longer overall survival

and better response. Low levels of PSMA5, another protein that makes part of

the proteasome itself and is used to measure the proteasome activity in the

cell, were correlated with better response and longer time to progression.

....Elevated levels of p27, a tumor suppressor protein, which accumulates

after proteasome inhibition, were significantly associated with longer

overall survival as well.

" There are a multitude of pathways these types of drugs may affect, " said

Dr. Goy. " The biomarkers help us identify the most promising. Moving

forward, this will give us new tools to see how cells are wired and identify

those patients who might benefit most from a particular drug. "

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm